Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (NYSE:TEVA) announced its Q2 2026 Aide Memoire is now available on the investors page of its website. The document compiles previously disclosed public information to help investors prepare for second quarter 2026 results, expected on July 29, 2026, at 7:00 a.m. ET, followed by an earnings conference call at 8:00 a.m. ET.
Teva (NYSE:TEVA) submitted a New Drug Application to the FDA for ecopipam, a first-in-class investigational therapy for pediatric Tourette syndrome. The drug is a selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.
The NDA is backed by Phase 3 data in JAMA Neurology showing ecopipam significantly delayed time to relapse versus placebo (primary endpoint p = 0.008) and was generally well tolerated, with common adverse events including somnolence, insomnia, anxiety, fatigue and headache.
Teva (NYSE:TEVA) will publish its second quarter 2026 financial results on July 29, 2026 at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. Investors must register in advance for dial-in details. A webcast replay will be available within 24 hours.
Teva (NYSE:TEVA) closed its acquisition of Emalex Biosciences, adding ecopipam, a late-stage investigational treatment for pediatric Tourette syndrome, to its neuroscience pipeline. Teva paid $700 million upfront, with up to $200 million in potential commercial milestones, plus net sales-based royalties.
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. Phase 3 data were published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026, supporting Teva’s Pivot to Growth strategy.
Teva (NYSE:TEVA) reported new data on AUSTEDO and AUSTEDO XR for tardive dyskinesia. Real-world IMPACT-TD results showed AIMS score reductions in all participants with mild TD at three months and better daily functioning. Three-year RIM-TD data indicated rising response rates with sustained treatment, while caregiver education efforts improved TD discussions and diagnoses.
Teva (NYSE:TEVA) reported new real-world survey data on AUSTEDO and AUSTEDO XR in Huntington’s disease (HD) chorea. The decentralized myHDstory study found HD chorea frequently disrupted social life, emotional wellbeing, daily activities and vocational/recreational life for both patients and caregivers before treatment.
Among patients taking AUSTEDO or AUSTEDO XR, 74% reported improved chorea movements, with 60–71% reporting quality-of-life gains across domains and over 85% noting better daily activities and social goals. Seventy-seven percent of caregivers reported improvements in social and emotional wellbeing goals as chorea impact declined.
Teva (NYSE: TEVA) launched AHZANTIVE (aflibercept), an EMA-approved biosimilar to Eylea, across several European markets, including France, Germany, Spain and The Netherlands.
The pre-filled syringe launch, begun in May 2026, supports Teva’s Pivot to Growth strategy and expands its ophthalmology biosimilars portfolio.
Teva (NYSE:TEVA) announced that President and CEO Richard Francis will take part in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 8:00 A.M. Eastern Time.
Investors can access a live webcast and 30-day replay via Teva’s investor relations website.
Teva (NYSE: TEVA) and Medincell (Euronext: MEDCL) announced EMA acceptance of the Marketing Authorization Application for olanzapine long-acting injectable TEV-‘749 to treat adult schizophrenia.
The investigational subcutaneous injection is given every four weeks and is supported by a Phase 3 program, including SOLARIS.
TEV-‘749 uses Medincell’s SteadyTeq copolymer technology for controlled drug release and has shown efficacy, a systemic safety profile, and exposure consistent with oral olanzapine. TEV-‘749 is not approved by any regulatory authority worldwide.
Teva (NYSE:TEVA) and Medincell announced that the European Medicines Agency has accepted the Marketing Authorization Application for olanzapine long-acting injectable TEV-‘749 to treat schizophrenia in adults.
TEV-‘749 is a subcutaneous, once-every-four-weeks formulation supported by a Phase 3 program and is not yet approved anywhere.